skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

About Louisa

UK

+5 year(s) experience

Louisa-Joseph-Pharmaintelligence
Louisa Joseph is an Analyst on the Cardiovascular and Metabolic team. Her disease areas include dyslipidemia, heart failure and ACS. By following market events and trends, she provides high-quality analysis from both clinical and commercial perspectives.

Louisa develops and delivers high-impact research regarding key trends and events in the pharmaceutical and biotechnology industries. She produces pipeline and marketed drug analyses, 10 year-patient/sales based forecasts and in-depth pre/post-conference opinion pieces.

She has a particular interest in analyzing the development of novel therapies from the early pre-clinical and clinical phases through final approval and marketing authorization.

Louisa joined Datamonitor Healthcare in June 2015, after completing a bachelor’s degree in Biochemistry and Pharmacology at the University of Bristol.

Analyst Articles

Articles by Louisa

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...

    Pricing and reimbursement of curative therapies continues to dominate ISPOR discussions

    Pricing and reimbursement of curative therapies continues to dominate ISPOR discussions

    Commentators at the ISPOR Europe 2019 conference in Copenhagen debated the challenges that exist with valuing and financing potentially curative treatments, including cell and gene therapies, and cancer immunotherapies. With several recent regulatory approvals of high-cost advanced therapy medicinal products (ATMPs), discussion has ensued in earnest on how to determine their clinical value, and whether traditional reimbursement and health technology assessment (HTA) processes are sufficient to assess these innovative treatments.

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート

    Global Market Access Webinar

    Join subject-matter experts from Datamonitor Healthcare as they use data and their industry experience to examine the challenges and opportunities brought about by recent global trends in market access. Learn how to navigate this complex terrain, as increasingly restrictive pricing and reimbursement policies are having an adverse effect on sales of launched and pipeline products across many global markets.

    Topic reimbursement

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート

    PCSK9 inhibitors recommended for limited patient groups

    A US Food and Drug Administration (FDA) committee has endorsed Praluent (alirocumab; Sanofi/Regeneron) and Repatha (evolocumab; Amgen/Astellas) solely for high-risk hypercholesterol 

    Topic vaccines